Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Go back to Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)| Amgen Inc (NASDAQ: AMGN) | Delayed: 382.86 +3.08 (0.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $379.78 | 52 Week High | $176.85 | |||
| Open | $378.51 | 52 Week Low | $133.64 | |||
| Day High | $385.60 | P/E | 57.66 | |||
| Day Low | $378.51 | EPS | $6.64 | |||
| Volume | 2,070,606 | |||||
